1. A supreme (court) biosimilar battle brewing

How often does the US Supreme Court hear a case involving the pharmaceutical industry? We don’t know, but it’s not every day, of that we are pretty sure. Just last week the US Solicitor General (sounds made up, right?) called on the Supreme Court to review the six-month delays to biosimilar launches. Believe it or not, after (yes, after) the FDA gives the okay for a company to start marketing a biosimilar, the originator company has six additional months to identify any potential patent claims. Translation: originator companies get at least six more months of patent exclusivity. Translation of the translation: mucho dinero. So, yes, this is a big deal for the entire healthcare system in the US.